Skip to main content
. 2022 Apr 23;11(9):2363. doi: 10.3390/jcm11092363

Table 3.

Results of the most frequent antineoplastic agents in the study sample.

Group Drug n %
1 Docetaxel 10 11.1
2 Cyclophosphamide + Docetaxel 14 15.5
3 Cyclophosphamide + Doxorubicin 15 16.7
4 Doxorubicin + Cyclophosphamide+Docetaxel 16 17.8
5 Docetaxel + other antineoplastic agents 15 16.7
6 Other combinations of antineoplastic agents 20 22.2